Best AI News today

tempus ai — AI News Today

235 stories

12 from search

What's happening with tempus ai

We're tracking 235 stories on tempus ai across 70 sources — it's seeing steady coverage this week, with 2 published in the last 24 hours. 89 stories have been corroborated by 3+ independent outlets. The most-covered angle right now: Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform (20 sources).

Synthesized live from 70 sources · updated every 15 minutes

235 stories
1 of 5 Top Stories
Breaking
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
BreakingMedia

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Tempus, the AI-driven oncology company valued at $8.1 billion, is acquiring Personalis in an all-stock deal that would give it direct control of molecular residual disease testing—a blood-based technology that can detect cancer recurrence months or years before conventional imaging, potentially transforming how doctors monitor patients for relapse. The combination represents a significant consolidation in precision oncology just as major health systems and pharmaceutical companies are racing to integrate MRD testing into treatment protocols, a shift that could upend the economics of cancer care. By owning both the AI analysis engine and the underlying molecular data, Tempus is betting it can lock in a dominant position in a market that analysts say could reach

Business Wire faviconBusiness Wire·
RelatedTempus AIAI & Medicine

20 sources

Yahoo Finance faviconYahoo FinanceMedical Device Network faviconMedical Device NetworkMedCity News faviconMedCity News
Media

TEM to CAD: Tempus AI, Inc. • Robinhood Token Price in Canadian Dollar

CoinGecko faviconCoinGecko·
Media

FDA Approves Tempus’ Tumor Only xT CDx

Medical Product Outsourcing faviconMedical Product Outsourcing·
Media

Tempus AI Expands Cancer Platform With Launch of ArteraAI Prostate Test For Metastatic Patients

Stocktwits faviconStocktwits·
Media

Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside

Yahoo Finance faviconYahoo Finance·
RelatedTempus AI
Finivi Inc. Sells 24,340 Shares of Tempus AI, Inc. $TEM
Media

Finivi Inc. Sells 24,340 Shares of Tempus AI, Inc. $TEM

MarketBeat faviconMarketBeat·
RelatedTempus AI

6 sources

MarketBeat faviconMarketBeatYahoo Finance faviconYahoo Finance
Media

Why Tempus AI (TEM) Is Up 18.6% After Joining CellCarta’s CDx Commercialization Lab Network

simplywall.st faviconsimplywall.st·
RelatedTempus AI

3 sources

simplywall.st faviconsimplywall.stPR Newswire faviconPR Newswire
Dimensional Fund Advisors LP Has $1.85 Million Stock Holdings in Tempus AI, Inc. $TEM
Media

Dimensional Fund Advisors LP Has $1.85 Million Stock Holdings in Tempus AI, Inc. $TEM

MarketBeat faviconMarketBeat·
Media

Bios Life Emerges from Stealth with $25M and Partners with Tempus to Personalize Cancer Screening and Surveillance

SynBioBeta faviconSynBioBeta·
Media

Tempus AI CEO, data Ryan Fukushima sells $1,000,800 in shares

Investing.com faviconInvesting.com·
RelatedTempus AI

5 sources

Investing.com faviconInvesting.comMarketBeat faviconMarketBeat
Media

Bios Life leaves stealth with $25M and a Tempus alliance for cancer surveillance

The Next Web faviconThe Next Web·
Media

Tempus AI Stock (TEM) Opinions on Analyst Ratings and Portfolio Holdings

Quiver Quantitative faviconQuiver Quantitative·
Tempus AI Stock Drops As $1.5B Personalis Deal Ups The MRD Stakes
Media

Tempus AI Stock Drops As $1.5B Personalis Deal Ups The MRD Stakes

StocksToTrade faviconStocksToTrade·
Media

Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead

TradingView faviconTradingView·
Media

Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

Yahoo Finance faviconYahoo Finance·
RelatedTempus AI
Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $1,000,800.00 in Stock
Media

Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $1,000,800.00 in Stock

MarketBeat faviconMarketBeat·
RelatedTempus AI

9 sources

MarketBeat faviconMarketBeatInvesting.com faviconInvesting.com
Media

Tempus AI (NASDAQ:TEM) Trading 7.5% Higher - Still a Buy?

MarketBeat faviconMarketBeat·
RelatedTempus AI
Media

Tempus AI (TEM) After CellCarta Deal And PRISM2 Validation Faces A Fresh Valuation Test

simplywall.st faviconsimplywall.st·
Why is Tempus AI stock surging on Friday?
Media

Why is Tempus AI stock surging on Friday?

Tempus AI Inc. TEM stock is surging over 11% on Friday at the time of publication. The price movement is primarily driven by a broader AI-healthcare technology sector rally sparked by stellar...

Benzinga on MSN faviconBenzinga on MSN·

Frequently Asked Questions

What is tempus ai?

tempus ai is a trending topic in artificial intelligence. Best AI News Today aggregates the latest news and developments about tempus ai from over 30 sources including research papers, tech publications, and community discussions.

What are the latest news about tempus ai?

As of today, there are 235 recent stories about tempus ai. Recent headlines include: TEM to CAD: Tempus AI, Inc. • Robinhood Token Price in Canadian Dollar; Dimensional Fund Advisors LP Has $1.85 Million Stock Holdings in Tempus AI, Inc. $TEM; Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead. This page is updated every 15 minutes with the latest coverage.

Where can I find tempus ai discussions?

You can find tempus ai discussions on Reddit AI communities, Hacker News, and other tech forums. Best AI News Today aggregates discussions from these platforms alongside research publications and tech media coverage.